Trial reportEuropean heart journal2013
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
Trial report in European heart journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Pharmacological interventions for heart failure in people with chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- Re-PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients.ESC heart failure · 2025Trial
- Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX-AHF-2 trial.European journal of heart failure · 2024Trial
- Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial.ESC heart failure · 2019Trial
- Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Trial
- Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study.Clinical research in cardiology : official journal of the German Cardiac Society · 2017Trial
- A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction.Cardiovascular research · 2025Article
- Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure.Biomolecules · 2021Article
- Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player.ESC heart failure · 2020Review
- Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study.Clinical research in cardiology : official journal of the German Cardiac Society · 2020Article
- Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.Journal of the American Heart Association · 2019Article
- KSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart Failure.Korean circulation journal · 2019Review
- Heart Disease and Relaxin: New Actions for an Old Hormone.Trends in endocrinology and metabolism: TEM · 2018Review
- The actions of relaxin on the human cardiovascular system.British journal of pharmacology · 2017Review
- Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials.Current heart failure reports · 2017Review
- Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Review
- Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs.Critical pathways in cardiology · 2015Review
- In a Class of Their Own - RXFP1 and RXFP2 are Unique Members of the LGR Family.Frontiers in endocrinology · 2015Review
- Emerging role of serelaxin in the therapeutic armamentarium for heart failure.Current atherosclerosis reports · 2014Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimPatients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial. METHODS AND
resultsSubgroups were based on pre-specified covariates (age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization). Other covariates which may modify the efficacy of AHF treatment were also analysed. Subgroup analyses did not show any difference in the effects of serelaxin vs. placebo on dyspnoea relief or on the incidence of cardiovascular death or rehospitalizations for heart failure or renal failure at 60 days. Nominally significant interactions between some patient subgroups and the effects of serelaxin on 180 days cardiovascular and all-cause mortality were noted but should be interpreted cautiously due to the number of comparisons and the low incidence of deaths in the subgroups at lower risk.
conclusionThe effects of serelaxin vs. placebo appeared to be similar across subgroups of patients in RELAX-AHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.